Oligo-Fucoidan improved skin health in in vitro and clinical study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220623004

Enrollment

Registered

2022-06-23

Start date

2015-10-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

skin sub-health person skin dysfunction

Interventions

Eighty female subjects, between 30 and 60 years of age, inclusive, were randomly allocated to use oligo-Fucoidan 5%, Argireline 3%, Hyaluronic acid 1%, EGF 1ppm cream. The following procedure was appl

Experimental Other

oligo-Fucoidan 5%, Argireline 3%, Hyaluronic acid 1%, EGF 1ppm

Eligibility

Sex/Gender

Female

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: female subjects, between 30 and 60 years of age

Exclusion criteria

Exclusion criteria: Serious skin disease, skin wounds, skin cancer

Design outcomes

Primary

Measure	Time frame
oligo-fucoidan inhibits inflammation At 0, 24, 48, 72, 96 and 120 h The levels of inflammatory cytokines assay, oligo-fucoidan inhibits the number of wrinkles after 14 days oligo-fucoidan inhibits	—

Secondary

Measure	Time frame
oligo-fucoidan increased collagen production after 14 days skin ultrasound analyzer	—

Countries

Taiwan

Contacts

Public ContactHsiaoFen Wang

Hungkuang University

sec@web.hk.edu.tw88642631 8652

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026